MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$65,475K
Free Cash flow
-$100,253K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Stock-based compensation
Accrued and other liabilities
Others
Negative Cash Flow Breakdown
Net loss
Purchase of marketable securitie...
Prepaid expense and other curren...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-109,473
-121,032
-91,097
-80,293
Depreciation and amortization
132
140
135
129
Accretion of discount and amortization of premium on debt securities, net
-
-
-
-1,451
Accretion of discount and amortization of premium on purchase of debt securities
-1,098
-843
-6,981
-
Accretion of loan exit fee and amortization of loan costs, net
-
-
-
843
Accretion of loan exit fee and amortization of loan costs
646
639
1,857
-
Reduction in the carrying amount of operating lease right-of-use assets
120
116
113
435
Stock-based compensation
15,863
13,208
10,965
9,745
Payment of vt-109 license fee
-
-
0
0
Upfront and milestone obligations under license agreements
0
15,000
-
-
Prepaid expense and other current assets
9,428
5,143
372
-606
Other assets
0
0
-1
108
Accounts payable
664
-7,966
3,625
4,793
Accrued and other liabilities
2,508
-437
7,208
3,915
Operating lease liabilities
-187
-182
-100
-520
Net cash used in operating activities
-100,253
-106,500
-69,994
-61,906
Upfront and milestone payments under license agreements
0
15,000
-
-
Payment of vt-109 license fee
-
-
0
0
Purchase of internal use software license
114
150
-
-
Purchase of property and equipment
0
23
102
133
Purchase of marketable securities
98,056
210,561
24,499
98,696
Proceeds from maturities of marketable securities
131,030
87,918
105,265
168,590
Proceeds from sale of marketable securities
-
-
0
0
Net cash provided by (used in) investing activities
32,860
-137,816
80,664
69,761
Proceeds from exercise of stock options and employee stock purchase plan
1,918
3,942
4,187
797
Proceeds from refinancing under loan and security agreement, net
0
-
0
0
Payment of deferred issuance costs related to unfunded loan commitments
0
-
0
0
Proceeds from short swing settlement
-
-
500
0
Proceeds from borrowings, net of costs
-
-
0
-
Repurchase of common stock
-
-
0
0
Proceeds from issuance of common stock in follow-on offerings
-
-
300,000
0
Payment of issuance costs and underwriting fees related to follow-on offerings
-
-
18,405
0
Net cash provided by financing activities
1,918
3,942
286,282
797
Net decrease in cash and cash equivalents
-65,475
-240,374
296,952
8,652
Cash and cash equivalents, beginning of period
114,351
354,725
57,773
92,646
Cash and cash equivalents, end of period
48,876
114,351
354,725
57,773
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$131,030K
(-43.60%↓ Y/Y)
Proceeds from exercise of
stock options and...
$1,918K
(-3.96%↓ Y/Y)
Net cash provided by
(used in) investing...
$32,860K
(-25.08%↓ Y/Y)
Net cash provided by
financing activities
$1,918K
(-91.21%↓ Y/Y)
Canceled cashflow
$98,170K
Net decrease in cash
and cash...
-$65,475K
(-50.43%↓ Y/Y)
Canceled cashflow
$34,778K
Stock-based compensation
$15,863K
(-7.86%↓ Y/Y)
Accrued and other
liabilities
$2,508K
(-24.44%↓ Y/Y)
Accounts payable
$664K
(-87.91%↓ Y/Y)
Accretion of loan exit fee
and amortization of...
$646K
Depreciation and
amortization
$132K
(-35.29%↓ Y/Y)
Reduction in the carrying
amount of operating...
$120K
(-86.68%↓ Y/Y)
Purchase of marketable
securities
$98,056K
(-47.63%↓ Y/Y)
Purchase of internal use
software license
$114K
Net cash used in
operating activities
-$100,253K
(8.20%↑ Y/Y)
Canceled cashflow
$19,933K
Net loss
-$109,473K
(14.62%↑ Y/Y)
Prepaid expense and
other current assets
$9,428K
(126.53%↑ Y/Y)
Accretion of discount and
amortization of premium on...
-$1,098K
Operating lease
liabilities
-$187K
(78.33%↑ Y/Y)
Buy us a coffee
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)